Welcome to our dedicated page for Decision Diagnos news (Ticker: DECN), a resource for investors and traders seeking the latest updates and insights on Decision Diagnos stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Decision Diagnos's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Decision Diagnos's position in the market.
Decision Diagnostics Corp. (DECN) announced an agreement for a six-month, 8% Promissory Note worth $300,000 with a major investor to support the launch of the GenViro! Swift Kit for Covid-19 testing. Additionally, six existing Promissory Notes with the same investor were extended for an additional four months. The GenViro! Swift Kit is set for release on September 26, 2020, in selected international markets. DECN continues to develop diabetic test strips and expand distribution agreements across various international regions.
Decision Diagnostics Corp (OTC PINK: DECN) plans to launch its International GenViro! Covid-19 Saliva Swift Kit on September 26, 2020, with an initial order of 100,000 kits to meet distributor demand and build inventory. The company aims to fulfill its first shipment of 50,000 kits to India.
The kits will retail at an introductory price of $8.95 and have undergone rigorous testing in Korea. DECN is also seeking FDA authorization for its product while collaborating with international distributors for certifications.
Decision Diagnostics Corp. (OTC PINK:DECN) has made significant progress towards FDA EUA approval for its Covid-19 GenViro! Swift Kit testing methodology. The company is collaborating with a Korea-based partner to finalize saliva and blood rapid testing kits. DECN is now selecting US testing labs and is in discussions with the LA Mayor's Covid-19 Task Force to enhance at-home testing. Preliminary results from Korea indicate high accuracy with less than 5% variance in known-negative tests. The company expects to submit a new FDA application by the end of September.
Decision Diagnostics Corp. (DECN) has issued an 'Open Letter' addressing FDA's new guidelines for at-home rapid testing for COVID-19. CEO Keith Berman critiques the current definitions and regulatory requirements, arguing they may hinder public adoption of these tests. DECN claims its Swift Kits can deliver results in under 10.5 seconds, presenting a viable option against the backdrop of existing lengthy and costly testing methods. The letter emphasizes the urgent need for quicker regulations to facilitate effective testing.
FAQ
What is the current stock price of Decision Diagnos (DECN)?
What is the market cap of Decision Diagnos (DECN)?
